Patents by Inventor Janika VIERECK

Janika VIERECK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20220348920
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: July 12, 2022
    Publication date: November 3, 2022
    Inventors: Thomas THUM, Kumarswamy REGALLA, Janika VIERECK
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20220315924
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 6, 2022
    Inventors: Thomas THUM, Kumarswamy REGALLA, Janika VIERECK
  • LncRNAs for therapy and diagnosis of cardiac hypertrophy
    Patent number: 11371043
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 28, 2022
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Kumarswamy Regalla, Janika Viereck
  • LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
    Patent number: 11186838
    Abstract: The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: November 30, 2021
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Maria-Teresa Piccoli, Janika Viereck, Shashi Kumar Gupta
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20200165604
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: June 25, 2018
    Publication date: May 28, 2020
    Inventors: THOMAS THUM, KUMARSWAMY REGALLA, JANIKA VIERECK
  • The LNCRNA MEG3 for Therapy and Diagnosis of Cardiac Remodelling
    Publication number: 20190136236
    Abstract: The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Inventors: Thomas THUM, Maria-Teresa PICCOLI, Janika VIERECK, Shashi Kumar GUPTA
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20170183652
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: April 22, 2015
    Publication date: June 29, 2017
    Inventors: Thomas THUM, Kumarswamy REGALLA, Janika VIERECK